In vitro studies using freshly-isolated healthy donor T cells stimulated with Blinatumomab, a CD19xCD3 bispecific T cell engager (BiTE) approved for pediatric B-ALL, demonstrated that tumor cell surface molecules other than CD19 modulate the magnitude of T cell activation, proliferation, and ultimately tumor cell killing10. The gene discussed is CD19; the disease is neoplasm.